|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Song P, Cai Y, Tang H, Li C and Huang J:
The clinical management of hepatocellular carcinoma worldwide: A
concise review and comparison of current guidelines from 2001 to
2017. Biosci Trends. 11:389–398. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ozer Etik D, Suna N and Boyacioglu AS:
Management of hepatocellular carcinoma: Prevention, surveillance,
diagnosis, and staging. Exp Clin Transplant. 15 (Suppl 2):S31–S35.
2017.
|
|
4
|
Kulik LM: Advancements in hepatocellular
carcinoma. Curr Opin Gastroenterol. 23:268–274. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Clark T, Maximin S, Meier J, Pokharel S
and Bhargava P: Hepatocellular carcinoma: Review of epidemiology,
screening, imaging diagnosis, response assessment, and treatment.
Curr Probl Diagn Radiol. 44:479–486. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nishikawa H, Kita R, Kimura T and Osaki Y:
Transcatheter arterial embolic therapies for hepatocellular
carcinoma: A literature review. Anticancer Res. 34:6877–6886.
2014.PubMed/NCBI
|
|
7
|
Pastorelli D, Cartei G, Zustovich F,
Marchese F, Artioli G, Zovato S, Binato S, Ceravolo R, Cingarlini
S, Salmaso F, et al: Gemcitabine and liposomal doxorubicin in
biliary and hepatic carcinoma (HCC) chemotherapy: Preliminary
results and review of the literature. Ann Oncol. 17 (Suppl
5):v153–v157. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yang JX, Rastetter RH and Wilhelm D:
Non-coding RNAs: An introduction. Adv Exp Med Biol. 886:13–32.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wei L, Wang X, Lv L, Liu J, Xing H, Song
Y, Xie M, Lei T, Zhang N and Yang M: The emerging role of microRNAs
and long noncoding RNAs in drug resistance of hepatocellular
carcinoma. Mol Cancer. 18:1472019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kondo Y, Shinjo K and Katsushima K: Long
non-coding RNAs as an epigenetic regulator in human cancers. Cancer
Sci. 108:1927–1933. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Weidle UH, Birzele F, Kollmorgen G and
Ruger R: Long non-coding RNAs and their role in metastasis. Cancer
Genomics Proteomics. 14:143–160. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu L, Pan C, Wei X, Shi Y, Zheng J, Lin X
and Shi L: lncRNA KRAL reverses 5-fluorouracil resistance in
hepatocellular carcinoma cells by acting as a ceRNA against
miR-141. Cell Commun Signal. 16:472018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huang H, Chen J, Ding CM, Jin X, Jia ZM
and Peng J: LncRNA NR2F1-AS1 regulates hepatocellular carcinoma
oxaliplatin resistance by targeting ABCC1 via miR-363. J Cell Mol
Med. 22:3238–3245. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xiao J, Lv Y, Jin F, Liu Y, Ma Y, Xiong Y,
Liu L, Zhang S, Sun Y, Tipoe GL, et al: LncRNA HANR promotes
tumorigenesis and increase of chemoresistance in hepatocellular
carcinoma. Cell Physiol Biochem. 43:1926–1938. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li Y, Ye Y, Feng B and Qi Y: Long
noncoding RNA lncARSR promotes doxorubicin resistance in
hepatocellular carcinoma via modulating PTEN-PI3K/Akt pathway. J
Cell Biochem. 118:4498–4507. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Loewer S, Cabili MN, Guttman M, Loh YH,
Thomas K, Park IH, Garber M, Curran M, Onder T, Agarwal S, et al:
Large intergenic non-coding RNA-RoR modulates reprogramming of
human induced pluripotent stem cells. Nat Genet. 42:1113–1117.
2010. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Y, Xu Z, Jiang J, Xu C, Kang J, Xiao
L, Wu M, Xiong J, Guo X and Liu H: Endogenous miRNA sponge
lincRNA-RoR regulates Oct4, Nanog, and Sox2 in human embryonic stem
cell self-renewal. Dev Cell. 25:69–80. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hou P, Zhao Y, Li Z, Yao R, Ma M, Gao Y,
Zhao L, Zhang Y, Huang B and Lu J: LincRNA-ROR induces
epithelial-to-mesenchymal transition and contributes to breast
cancer tumorigenesis and metastasis. Cell Death Dis. 5:e12872014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhou X, Gao Q, Wang J, Zhang X, Liu K and
Duan Z: Linc-RNA-RoR acts as a ‘sponge’ against mediation of the
differentiation of endometrial cancer stem cells by microRNA-145.
Gynecol Oncol. 133:333–339. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gao S, Wang P, Hua Y, Xi H, Meng Z, Liu T,
Chen Z and Liu L: ROR functions as a ceRNA to regulate Nanog
expression by sponging miR-145 and predicts poor prognosis in
pancreatic cancer. Oncotarget. 7:1608–1618. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang S, Liu F, Deng J, Cai X, Han J and
Liu Q: Long noncoding RNA ROR regulates proliferation, invasion,
and stemness of gastric cancer stem cell. Cell Reprogram.
18:319–326. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li C, Lu L, Feng B, Zhang K, Han S, Hou D,
Chen L, Chu X and Wang R: The lincRNA-ROR/miR-145 axis promotes
invasion and metastasis in hepatocellular carcinoma via induction
of epithelial-mesenchymal transition by targeting ZEB2. Sci Rep.
7:46372017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Takahashi K, Yan IK, Haga H and Patel T:
Modulation of hypoxia-signaling pathways by extracellular linc-RoR.
J Cell Sci. 127:1585–1594. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Takahashi K, Yan IK, Kogure T, Haga H and
Patel T: Extracellular vesicle-mediated transfer of long non-coding
RNA ROR modulates chemosensitivity in human hepatocellular cancer.
FEBS Open Bio. 4:458–467. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Odero-Marah V, Hawsawi O, Henderson V and
Sweeney J: Epithelial-mesenchymal transition (EMT) and prostate
cancer. Adv Exp Med Biol. 1095:101–110. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yee NS: Update in systemic and targeted
therapies in gastrointestinal oncology. Biomedicines. 6:342018.
View Article : Google Scholar
|
|
28
|
Kudo M: Systemic therapy for
hepatocellular carcinoma: 2017 update. Oncology. 93 (Suppl
1):S135–S146. 2017. View Article : Google Scholar
|
|
29
|
Nishida N, Kitano M, Sakurai T and Kudo M:
Molecular mechanism and prediction of sorafenib chemoresistance in
human hepatocellular carcinoma. Dig Dis. 33:771–779. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lohitesh K, Chowdhury R and Mukherjee S:
Resistance a major hindrance to chemotherapy in hepatocellular
carcinoma: An insight. Cancer Cell Int. 18:442018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li C, Chen J, Zhang K, Feng B, Wang R and
Chen L: Progress and prospects of long noncoding RNAs (lncRNAs) in
hepatocellular carcinoma. Cell Physiol Biochem. 36:423–434. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li CH and Chen Y: Targeting long
non-coding RNAs in cancers: Progress and prospects. Int J Biochem
Cell Biol. 45:1895–1910. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen Y, Shen Z, Zhi Y, Zhou H, Zhang K,
Wang T, Feng B, Chen Y, Song H, Wang R and Chu X: Long non-coding
RNA ROR promotes radioresistance in hepatocelluar carcinoma cells
by acting as a ceRNA for microRNA-145 to regulate RAD18 expression.
Arch Biochem Biophys. 645:117–125. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pan Y, Li C, Chen J, Zhang K, Chu X, Wang
R and Chen L: The emerging roles of long noncoding RNA ROR
(lincRNA-ROR) and its possible mechanisms in human cancers. Cell
Physiol Biochem. 40:219–229. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lou Y, Jiang H, Cui Z, Wang L, Wang X and
Tian T: Linc-ROR induces epithelial-to-mesenchymal transition in
ovarian cancer by increasing Wnt/β-catenin signaling. Oncotarget.
8:69983–69994. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pan Y, Chen J, Tao L, Zhang K, Wang R, Chu
X and Chen L: Long noncoding RNA ROR regulates chemoresistance in
docetaxel-resistant lung adenocarcinoma cells via epithelial
mesenchymal transition pathway. Oncotarget. 8:33144–33158. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sahebi R, Malakootian M, Balalaee B,
Shahryari A, Khoshnia M, Abbaszadegan MR, Moradi A and Javad Mowla
S: Linc-ROR and its spliced variants 2 and 4 are significantly
up-regulated in esophageal squamous cell carcinoma. Iran J Basic
Med Sci. 19:1131–1135. 2016.PubMed/NCBI
|
|
38
|
Shi J, Zhang W, Tian H, Zhang Q and Men T:
lncRNA ROR promotes the proliferation of renal cancer and is
negatively associated with favorable prognosis. Mol Med Rep.
16:9561–9566. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chaffer CL, San Juan BP, Lim E and
Weinberg RA: EMT, cell plasticity and metastasis. Cancer Metastasis
Rev. 35:645–654. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zheng HC: The molecular mechanisms of
chemoresistance in cancers. Oncotarget. 8:59950–59964. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kang Y and Massagué J:
Epithelial-mesenchymal transitions: Twist in development and
metastasis. Cell. 118:277–279. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang Y, Sun B, Zhao X, Zhao N, Sun R, Zhu
D, Zhang Y, Li Y, Gu Q, Dong X, et al: Twist1-related miR-26b-5p
suppresses epithelial-mesenchymal transition, migration and
invasion by targeting SMAD1 in hepatocellular carcinoma.
Oncotarget. 7:24383–24401. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang D, Han S, Wang X, Peng R and Li X:
SOX5 promotes epithelial-mesenchymal transition and cell invasion
via regulation of Twist1 in hepatocellular carcinoma. Med Oncol.
32:4612015.PubMed/NCBI
|
|
44
|
Liu YR, Liang L, Zhao JM, Zhang Y, Zhang
M, Zhong WL, Zhang Q, Wei JJ, Li M, Yuan J, et al: Twist1 confers
multidrug resistance in colon cancer through upregulation of
ATP-binding cassette transporters. Oncotarget. 8:52901–52912. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ávila-Moreno F, Armas-López L,
Álvarez-Moran AM, López-Bujanda Z, Ortiz-Quintero B,
Hidalgo-Miranda A, Urrea-Ramírez F, Rivera-Rosales RM,
Vázquez-Manríquez E, Peña-Mirabal E, et al: Overexpression of MEOX2
and TWIST1 is associated with H3K27me3 levels and determines lung
cancer chemoresistance and prognosis. PLoS One. 9:e1141042014.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang R, Li Y, Hou Y, Yang Q, Chen S, Wang
X, Wang Z, Yang Y, Chen C, Wang Z and Wu Q: The
PDGF-D/miR-106a/Twist1 pathway orchestrates epithelial-mesenchymal
transition in gemcitabine resistance hepatoma cells. Oncotarget.
6:7000–7010. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Xue F, Liu Y, Chu H, Wen Y, Yan L, Tang Q,
Xiao E, Zhang D and Zhang H: eIF5A2 is an alternative pathway for
cell proliferation in cetuximab-treated epithelial hepatocellular
carcinoma. Am J Transl Res. 8:4670–4681. 2016.PubMed/NCBI
|
